Most US states have no peptide-specific law. As of September 26, 2026, we verified state actions in six states, and most are notices from medical or pharmacy boards telling licensed providers and clinics not to use "research-grade" peptides with patients. Louisiana is the only state we found with a new statute, and it expands access to pharmacy-compounded peptides rather than restricting research sales. Everywhere, federal FDA rules still apply.
Notice: This is a plain-language summary of public sources, not legal advice. Research peptides are sold for in-vitro laboratory research only. They are not FDA-approved and not for human or animal consumption. Rules change often, so check your state's boards or a lawyer for your situation. Last reviewed September 26, 2026.
For the federal picture, see are peptides legal? and the dated peptide regulatory news tracker. This page is only about state-level actions.
How we built this list
We searched state medical, nursing and pharmacy board sites, state legislatures, attorney general press releases, and law-firm and trade-press summaries. We included an item only if we could confirm it on a government site or a named, credible report. We left out:
- State rules that cover GLP-1 compounding generally but not peptides or research-use products.
- Claims on vendor or marketing sites that we couldn't trace to a state source.
- Pending bills we couldn't confirm on a legislature site.
If we've missed a verified action, send us the source and we'll add it.
State actions on peptides (as of September 26, 2026)
| State | Date | Who | Action | Source |
|---|---|---|---|---|
| Alabama | Nov 10, 2025; settled Jan 12, 2026 | Attorney General | Sued a Cullman IV clinic, Aurora IV and Wellness, alleging it used "research-grade" tirzepatide and semaglutide advertised as "pharmaceutical-grade"; a court granted a temporary restraining order. The settlement closed the clinic permanently | AG complaint release, AG settlement release |
| Alabama | May 26, 2026 (per news reports) | Board of Medical Examiners | Official notice: "under no circumstances is it permissible for a physician to compound, administer, or dispense a non-FDA approved or research grade peptide"; patient consent forms don't remove liability | ALBME notice, Alabama Reporter |
| Connecticut | May 21, 2025; settled Aug 5, 2025 | Attorney General | Sued Triggered Brand over "research grade" GLP-1 peptides marketed for weight loss, under the state unfair trade practices law. Settlement: stop sales, $300,000 judgment ($18,500 paid, rest suspended) | AG suit release, AG settlement release |
| Connecticut | May 6, 2026 | Attorney General | Settlement with the Made-in-China platform to stop sales of "research grade" GLP-1s into the US and remove listings within five days; $300,000 penalty, suspended after $30,000 | AG release |
| Louisiana | Signed May 22, 2026; effective Aug 1, 2026 | Legislature (SB 253, Act 374) | Bars licensing boards from prohibiting prescribers from providing peptides prepared by FDA-registered 503B outsourcing facilities or 503A pharmacies that meet federal requirements, and protects in-state pharmacists who compound them. Passed 35-0 and 98-0 | Legislature bill page, bill text |
| Mississippi | Aug 19, 2026 | Board of Medical Licensure, Board of Nursing, Board of Pharmacy (joint) | Joint statement: "Under no circumstances is it permissible for a healthcare provider to compound, administer, or dispense a non-FDA approved or research-grade peptide"; consent forms don't remove liability | Signed statement (PDF), MSBML page |
| Ohio | Guidance updated Dec 8, 2025 | Board of Pharmacy | Guidance for prescriber clinics and med spas: any medication labeled "for research purposes only" is "unlawful to possess by prescriber clinics and med spas," regardless of patient consent; dispose of it immediately | Board guidance (PDF) |
| South Carolina | Mid-August 2026 (per LumaLex Law; notice undated) | Board of Medical Examiners | "Notice Concerning the Prescribing of Research-Grade Peptides and FDA-Ineligible Peptides": physicians may not compound, administer, prescribe or dispense research-grade or FDA-ineligible peptides; buying from unpermitted facilities can be aiding unlicensed practice | BME notice (PDF), LumaLex Law |
States are listed alphabetically.
Notes on the table
Board notices apply to licensees. The Alabama, Mississippi, South Carolina and Ohio items tell physicians, nurses, pharmacists or clinics what they may not do with patients. They don't create new crimes for the public. Mississippi's statement adds that when a patient "independently acquires and self-administers such substances, the associated risk rests solely with the patient."
Ohio has enforced its position. A January 2026 Frier Levitt analysis reports that the Ohio Board of Pharmacy used summary suspensions and settlements against clinics and distributors, and characterized AOD-9604, BPC-157 and ipamorelin as unapproved or not permitted to be compounded.
Louisiana moves the other way. Act 374 is about lawful compounding. It limits what licensing boards can prohibit when a peptide comes from a compliant 503A or 503B pharmacy. It doesn't make research-use-only products legal for people. Federal compounding rules still decide which peptides pharmacies can use; see the July 2026 advisory committee votes in our news tracker.
The AG cases involve GLP-1 drugs. Every attorney general action we verified concerned research-grade semaglutide, tirzepatide or other GLP-1 products. We include them because they target the "research grade" sales model itself.
Multi-state and model-bill context
Two items aren't state law but show where states are heading:
- February 19, 2025: 38 state and territory attorneys general, co-led by South Carolina, Colorado, Illinois and Tennessee, asked FDA to act against GLP-1 ingredients sold "for research purposes only" while marketed to consumers (NAAG).
- August 12, 2026: the American Legislative Exchange Council finalized a model "American Peptide Access Act" that would stop licensing boards from disciplining providers and pharmacists for lawfully prescribed, compounded peptides. It's a template, and the page names no state that has adopted it. Louisiana's Act 374 takes a similar approach.
The other 44 states
We found no verified peptide-specific statute, board notice or AG action in the remaining states as of September 26, 2026. That doesn't mean peptides are unregulated there. In every state:
- Federal law applies. FDA treats research-use-only peptides as unapproved new drugs when marketing shows they're meant for people, and it has sent warning letters to sellers across the country (FDA peptide regulation 2026).
- General state drug and pharmacy laws apply. A Sheppard Mullin review found that most state action so far has focused on GLP-1 compounding, not the broader peptide category, and that states such as Texas and Florida build on federal compounding standards.
- Licensed providers have standard-of-care duties whether or not their board has issued a peptide notice, as LumaLex Law notes in its Mississippi and South Carolina analysis.
This page is about state rules, not product quality. For vendors that document testing, see best peptide vendors in the USA, which is an editors' ranking, not a sort by score (how we rank). Use the COA checklist to review a certificate and the peptide reconstitution calculator for lab concentration math.
Last reviewed September 26, 2026. We'll add state actions as we verify them. Next scheduled review: October 2026.